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OBJECTIVES: To identify prognostic factors associated with longer transplant
hospitalization in pediatric allogeneic hematopoietic cell transplant (allo-HCT)
recipientswith adenovirus (AdV) infection.METHODS: AdVance is a retrospective,
Europeanmultinational study into allo-HCT recipients who develop AdV infection.
Here we focus on predictors of increased length of hospitalization. Review of
medical chart data for the six months following allo-HCT identified patients with
AdV infection. Fine-Gray multivariate regression models were utilized to identify
prognostic factors associated with longer transplant hospitalization in pediatric
patients who developed AdV infection following allo-HCT. Models accounted for
death as a competing risk and data were censored at one year after allo-HCT.
Transplant hospitalization was defined as the time from allo-HCT procedure until
hospital discharge. RESULTS: For the transplant hospitalization, median length of
stay was 50 days for patients with AdV viremia during the hospitalization (n¼263)
versus 34 days for those without AdV viremia (n¼295). Multivariate regression
analysis, controlling for age, race, and center effect as a fixed factor, revealed
factors independently associated with risk of longer transplant hospitalization:
AdV viremia10,000 copies/mL (HR¼5.26; 95% CI: 3.13-8.33; p<0.0001) or from 1000
to 10,000 copies/mL (HR¼2.08; 95%CI: 1.32-3.33; p¼0.0017); lymphocyte counts <300
cells/mL (HR¼1.67; 95% CI: 1.15-2.38; p¼0.0062); and graft versus host disease
(GvHD) grade 3 (HR¼2.86; 95% CI: 1.89-4.35; p<0.0001) or grade 4 (HR¼6.25; 95% CI:
3.33-11.11; p<0.0001).CONCLUSIONS: AdV viremia in pediatric allo-HCT recipients
is a strong independent predictor of longer hospital stay following allo-HCT. Higher
viral burden is associated with increased risk of prolonged transplant hospitali-
zation, independent of other confirmed risk factors such as low lymphocyte counts
or GvHD. Approaches that prevent or mitigate high-level AdV viremia could
therefore reduce the healthcare resource burden associated with allo-HCT.
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OBJECTIVES: Considering the recent change of paradigm in chronic hepatitis C
virus (HCV) infection management, this research aimed to evaluate the annual per
patient healthcare costs associated to HCV management in Portugal, through a
detailed analysis of healthcare resource utilization (HRU).METHODS: A two-round
national expert panel was performed with specialist physicians from gastroen-
terology, infectious diseases and internal medicine. In the first round, experts
responded to an electronic questionnaire concerning annual HRU associated with
the different stages of liver disease (irrespective of HCV therapy) and treatment
monitoring during HCV therapy. The second round consisted of a focus group to
validate the results obtained from the questionnaires. Disease stages considered
were: fibrosis (METAVIR F0-3), compensated cirrhosis (METAVIR F4), decom-
pensated cirrhosis, hepatocellular carcinoma and post-liver transplant (LT). Hos-
pitalizations, medical appointments, laboratory tests and other exams were the
healthcare resources considered. HCV therapy and other drugs were not taken into
account. Costs were obtained multiplying mean estimates of annual HRU by unit
NHS costs retrieved from official sources. RESULTS: Elicited annual HRU costs per
liver disease stage were as follows: V498 for fibrosis, V1,359 for compensated
cirrhosis, V5,749 for decompensated cirrhosis, V6,347 for hepatocellular carci-
noma, V2,522 for the first year post-LT and V1,698 for subsequent years. Irre-
spective of disease stage, themajority of costs were related to hospitalizations and
medical appointments, especially for decompensated cirrhosis and hepatocellular
carcinoma (85%). Costs for other exams where residual, with the exception of
post-LT disease stages (20%). Treatment monitoring ranged from a low of V699
for 8-week HCV therapy in non-cirrhotic patients, to a high of V1,288 for 24-week
HCV therapy in cirrhotic patients. CONCLUSIONS: Decompensated cirrhosis and
hepatocellular carcinoma were the liver disease stages with highest annual HRU
costs associated to themanagement of HCV patients. Most of the costs incurred are
furthermore related to hospitalizations and medical appointments.
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OBJECTIVES: The prevalence of HIV in the older population has been increasing
dramatically in the last decade. However, little is known about the economicburden of HIV after the implementation of Part D, which covers all antiretroviral
medications. The objectives of this study, therefore, are to 1) assess the economic
burden of patients with HIV/AIDs compared to patients without HIV/AIDS; and 2)
examine the possible racial/ethnicity disparities in economic burden among
Medicare beneficiarieswith HIV/AIDS after Part D.METHODS: This study utilized a
cross-sectional design based on the Medicare Current Beneficiary Survey (MCBS)
data between 2006 and 2012. MCBS is a nationally representative survey linked to
Medicare Claims data. The economic burden of HIV/AIDs on patients’ out-of-
pocket costs, inpatient costs, out-patient costs, Medicare costs, and total medical
costs were investigated using Generalized Linear Model with a log-link and gamma
distribution. RESULTS: We identified a total of 73,383 eligible Medicare benefi-
ciaries. Patients with HIV/AIDS have significant higher economic burden compared
to their counterparts in terms of total medical care costs ($17212.2, P<0.001),
prescription drugs ($3755.2, P<0.001), Medicare spending (14923.8, P<0.001), out-of-
pocket spending ($670.0, P¼0.0009), inpatient spending ($6632.4, P<0.001) and out-
patient spending (1349.3, P <1349.3). After adjusting for covariates, HIV/AIDs
continued to pose higher economic burden. In addition, Non-Hispanic blacks,
Hispanics and other races had significantly lower out-of-pocket spending
compared to non-Hispanic Whites by 23.94 % (95 % CI:-27.26 % to -20.46 %), 14.62 %
(95 % CI:-19.04 % to -9.96 %), and 22.93 % (95 % CI:-26.97 % to -18.66 %), respectively.
CONCLUSIONS: Despite the efforts by the Center for Medicare and Medicaid Ser-
vices to provide benefits for Medicare patients with HIV/AIDS, our findings suggest
that HIV patients continue to face substantial economic burden compared to their
counterparts; Additionally, significant racial/ethnicity disparities in economic
burden exist among Medicare beneficiaries with HIV/AIDS.
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OBJECTIVES: Rotavirus is a common cause of severe diarrhea in children under
five. Two types of rotavirus vaccines (i.e., RV1 and RV5) have been introduced and
used on a voluntary basis in South Korea. We conducted a systematic review (SR)
on economic evaluation (EE) of rotavirus vaccines (RV). METHODS: We searched
for previous SR studies of EE for RV in August 2017 using databases such asMedline
and Embase. After identifying SR studies, additional search was performed to
include literatures published after or unincluded in the previous SR. Among the 11
SR studies identified, a study by Kotirum et al (2017) was selected based on inclu-
sion/exclusion criteria and quality assessment by A MeaSurement Tool to Assess
systematic Reviews. A total of 104 original articles were included in the Kotirum’s
study. Among the 36 original articles identified through additional search, 10 were
selected, resulting in 114 studies included in our analysis. RESULTS: About 44% of
the studies evaluated RV1 only, 22% RV5 only, and 33% both. The proportion of the
studies concluding RV as being cost-effective were 90% when evaluating RV1 only,
64% RV5 only, and 68% both. Whereas RV5-only studies were performed usually in
high-income countries (68%), RV1-only studies were performed mainly in lower
middle-income (32%) and upper middle-income countries (26%). Majority of
RV1-only studies (82%; 28 of 34 studies specifying funding sources) were funded by
non-profit organization, and 100% of these studies were concluded as being cost-
effective. RV5-only studies weremostly funded by profit organization (68%; 13 of 19
studies specifying sources), and 92% of these studies concluded as being cost-ef-
fective. CONCLUSIONS: Characteristics of global EE studies for RV were assessed
in this study. Our analysis would be helpful to support policy decision for adopting
RV in National Immunization Program in South Korea.
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OBJECTIVES: Currently, in Portugal, People Living with HIV (PLHIV) refill antire-
troviral therapy (ART) at Hospital Pharmacies (HP). We aimed to assess the impact
of transferring ARTs dispensing from HP to community pharmacies (CPs) in the
Portuguese setting. METHODS: Non-controlled, prospective observational study
conducted at CPs on PLHIV. Eligible participants were adult PLHIV on ART with
undetectable viral load. Participants were consecutively recruited during the
follow-up medical visits in a Lisbon public hospital and selected a CP of their
convenience for ART refill. Recruitment started in December 2016 and the study
was prematurely interrupted in October 2017. Self-administered questionnaires
were used to compare waiting time, ART adherence, health-related quality of life
and satisfaction with ART dispensing at HP (i.e., recalling the previous 6-months
ART dispensing experience in HP) versus ART dispensing at CPs. At each visit,
pharmacists collected data on drugs dispensed, pharmacists’ intervention and
characterization of access to the pharmacy (i.e., itinerary, travel modes and times).
RESULTS: 29 pharmacies recruited 43 PLHIV and none withdrew during the study.
All PLHIV were followed for at least 6 months (mean follow-up period: 218 days).
Waiting and travel times significantly decreased, 3.6 and 3.7 times, respectively,
with the change of dispensing setting. Walking was the most frequently used
travel mode in the itineraries to CPs (59.0%), whereas it accounted for 19.3% in the
V A L U E I N H E A L T H 2 1 ( 2 0 1 8 ) S 1 eS 4 8 1S234case of HP. PLHIV reported a significant increase in satisfaction levels regarding
waiting time, privacy, dispensing schedule and overall satisfaction (p<0.05). No
significant changes in health-related quality of life and ART adherencewere found.
CONCLUSIONS: For PLHIV with undetectable viral load, changing the ART
dispense setting from HP to CPs is feasible and may have a significant and positive
impact on PLHIV satisfaction and access times, while not compromising privacy,
quality of life and adherence to treatment.
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OBJECTIVES: The 90-90-90 target set for 2020 is fast approaching and guidelines
recommend antiretroviral therapy (ART) for HIV-positive people (HPP), regardless
of CD4 count, aiming to improve long-term patient health and to prevent HIV
transmission. The objective of this study was to compare the delay between HIV
diagnosis and ART initiation across the EU5. METHODS: Data from Ipsos’ EU5 HIV
TherapyMonitor Scope Study (Scope) were used. Scope is amedical chart review of
HPPs conducted at 3-month intervals (N¼206 physicians reporting on patients
January, February, and March). Physicians are requested to abstract data on
consecutive 7-8 HPPs initiating therapy and 7-8 HPPs switching therapy (i.e., no
untreated or stable patients). Data includes demographics, disease history, and
treatment patterns. Descriptive analysis was conducted using appropriate statis-
tical tests. RESULTS: The Scope data set had a total of N¼206 physicians and
Y¼1,516 initiating patients with a mean age of 36 (standard deviation ¼ 10.8). 75%
of patients were male and 24% female. The delay between diagnosis and ART
initiation is significantly lower (p<0.05) in Germany (3.8 months) than in Italy (11.4
months) the UK (10.2 months), and Spain (9 months). Across the EU5, 51% of HPPs
were diagnosed in physician offices (PO) and 15.7% in sexual health/family plan-
ning clinics (SH/FP). POs were the primary location of diagnosis in France (38.1%),
Germany (94.1%), Italy (36.8%), and Spain (62.7%). In the UK, significantly more
HPPs (p<0.05) were diagnosed in SH/FPs (47.9%). HPPs diagnosed in POs have
significantly shorter delays in treatment initiation (6.3 months) (p<0.05) compared
to those diagnosed at non-POs (9.2 months). CONCLUSIONS: HPPs in Italy, the UK,
and Spain had the greatest delay in ART initiation compared to Germany. Delay in
diagnosis to initiation could lead to higher transmission risk, impacting outcomes
and targets set for 2020.
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OBJECTIVES: Influenza is responsible for between 200 and 500 deaths each
year in Ireland. Immunisation is a crucial component in infection control.
Vaccinating priority groups such as healthcare workers is a vital focus of
infection prevention efforts. In late 2017, the Irish Health Service Executive
(HSE) recommended that 40% of all healthcare workers receive the influenza
vaccination in order to maximise protection of at-risk patients. The aim of this
research was to ascertain the uptake of the seasonal influenza vaccination in
a cohort of pharmacists and to evaluate pharmacists’ perceptions on barriers
and facilitators to vaccination. METHODS: An online survey was distributed
using LimeSurvey® version 2.6.6 across 84 pharmacies within an Irish commu-
nity pharmacy chain in January 2018. Quantitative data was managed and
analysed in IBM SPSS Statistics® version 22. Qualitative data was analysed using
thematic analysis. RESULTS: A total of 109/238 pharmacists (45.8%) completed
the survey. One-hundred and six of the respondents (97.2%) were trained to
administer the influenza vaccine. The majority of respondents (79.8%) received
the seasonal influenza vaccine during the 2017/18 influenza season. Prior to
being trained in influenza vaccine administration, 29/106 pharmacists (27.4%)
received the vaccine. There were no statistically significant differences in the
vaccination uptake rates between younger and older pharmacists (p¼ 0.509) and
between newly qualified and more experienced pharmacists (p¼ 0.875). Barriers
to vaccination included time restrictions, fear of side effects and concerns about
the effectiveness of the influenza vaccine. Facilitators to vaccination included
free of charge vaccination service, importance of patient protection and per-
sonal safety. CONCLUSIONS: Uptake of the seasonal influenza vaccination
among a cohort of pharmacists exceeded standards recommended by the Irish
HSE for the vaccination of healthcare workers. Allocation of vaccination ap-
pointments, incentives, and promotion of influenza vaccination benefits are
strategies that should be implemented to enhance vaccination service usage.
PIN79
ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT
INVESTMENT FROM THE NHS PERSPECTIVE: A REAL-WORLD-BASED
ANALYSIS FROM PITER DATA
Marcellusi A1, Viti R1, Kondili L2, Rosato S2, Vella S2, Mennini FS1
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic
Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 2Center for
Global Health, Istituto Superiore di Sanita, Rome, Italy
OBJECTIVES: We estimated the cost consequence of the National Health System
(NHS) investment on Direct-acting antiviral agents (DAA) according to Hepatitis C
Virus (HCV) treatment access policies in Italy. METHODS: A multistate 20-year
time horizon Markov model of HCV liver disease progression was developed.
Fibrosis stage, age and Genotypes distributions were derived from the Italian
Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. Treatment effi-
cacy, disease progression probabilities and direct costs by each health state wereobtained from the literature. Discounted break-even point in time (DBPT) was
defined as the period of time required for the cumulative costs saved to recover the
NHS investment on DAA treatment. Three different PITER enrolment periods,
which covered the full DAA access evolution in Italy, were considered.
RESULTS: Disease stages of 2657 patients, who had consecutively undergone a
DAA therapy from January 2015 to December 2017 in 30 PITER clinical centres, were
standardized for 1,000 patients. The investment on DAAs was considered equal to
V25 million, V15 million, V9 million during 2015, 2016 and 2017 respectively. For
patients treated in 2015, the DBPTwill not be achieved due to the disease severity of
treated patients. For 2016 and 2017, the estimated DBPT were 6.6 and 6.2 years,
respectively. The total cost saving after 20 years was V50.13 and V55.50 million for
1,000 patients treated from 2015 to 2017 respectively. CONCLUSIONS: This study
may be a useful tool for public decision-makers to understand how HCV epide-
miological profiles influence the economic burden of HCV.
PIN81
PHARMACISTS AS VACCINATORS: FIRST YEAR EXPERIMENTATION ON
SEASONAL INFLUENZA VACCINATION IN FRANCE
Silva ML1, Fischer A2, Sanchez-Largeois M2, Aulois-Griot M1
1University of Bordeaux, Bordeaux, France, 2Regional Health Agency Nouvelle Aquitaine,
Bordeaux, France
OBJECTIVES: For the first time, during the winter of 2017-18, French pharmacists
participated in the seasonal influenza vaccination campaign. This is part of an
experimentation on “pharmacists as vaccinators” established by the Health Min-
istry notably aiming at improving vaccination coverage by simplifying the vacci-
nationcircuit. This studyassessed thecriteriamotivatingpharmacists to complying
with the experimentation. METHODS: Pharmacists working in community phar-
macies in the Nouvelle Aquitaine (NA) Region, selected for the experimentation,
were identified in the database of the Regional Health Agency (ARS). We developed
an online questionnaire consisting of: (1) the characteristics of the pharmacists
and their practice, (2) seasonal influenza vaccination activities, (3) perceptions of
financial and non-financial incentives to complying with the experimentation. All
pharmacists of the NA Region, authorized or not to vaccinate against seasonal
influenza, were allowed to participate. RESULTS: 1418 pharmacists replied to our
questionnaire (response rate of 28,2%, n¼5002 pharmacists invited); the majority
were vaccinated against seasonal influenza (78.3%). Few respondents were unli-
censed to vaccinate (n¼219, 15.4%), which is not representative of the whole un-
licensed pharmacists of the NA Region (n¼2977). Almost all respondents declared
being requested by non-eligible people to be vaccinated beyond the Heath Minis-
try’s requirements for the experimentation: often primary influenza vaccination
(64.1%) and healthy adults (52.6%). More than half of the respondents rejected the
financial incentives as a criterion to participate in the experimentation, but
emphasized their commitment to public health and the possibility of diversifying
their pharmaceutical activities. CONCLUSIONS: This study provides evidence on
the large compliance of pharmacists and their perceptions regarding the first year
of the experimentation on influenza vaccination at community pharmacies in the
NA Region. Enlarging the pharmacists’ audience eligible for vaccination may be an
opportunity to immunize people notably those willing to pay for the vaccine.
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OBJECTIVES: Policymakers in the UK are considering modifying the pneumococcal
conjugate vaccination (PCV) program from a 2+1 to a 1+1 schedule. Our dynamic
transmissionmodel estimated an increase in invasive pneumococcal disease (IPD) in
<2 year-olds due to the proposed schedule. This study builds upon previous work by
investigatingdifferential riskof IPD in thosewhodonot receive theboosterdose in the
two schedules. METHODS: An established transmission dynamic model was
parameterized using UK serotype-specific IPD data and published literature to predict
5-year cumulative IPD incidence per 100,000. For children ages 1 - <2, IPD incidence
risk ratios (IRR) were calculated as the risk of IPD without a booster dose compared to
no booster dose. These IRR were then compared between 2+1 and 1+1 schedules.
Scenario analyses examined the impact of modeling assumptions and parameter
uncertainty. RESULTS: For a 2+1 schedule, the model predicted a 5-year cumulative
IRR of vaccine-type IPD in 1 - <2 year-olds of 1.08 for those whomiss the booster dose
versus those receiving the booster dose. In a 1+1 schedule, this IRR was 1.37, a 27.3%
relative increase compared to a 2+1 schedule. Scenario analyses found that effec-
tiveness of a priming dosewas themain driver of increased diseasewhen individuals
miss a booster, with relative increases ranging from 16.7% to 45.6%.
CONCLUSIONS: Results demonstrate continued use of a 2+1 schedule would provide
greater IPD protection to younger populations than the proposed 1+1 schedule. This
outcome ismagnified if single priming dose effectiveness is lower than hypothesized.
Policymakers should consider the decreased protection afforded to childrenwhomay
be more likely to miss their booster dose.
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OBJECTIVES: To evaluate the cost-effectiveness of tender criteria in the national
pneumococcal conjugate vaccine immunization program and to use Slovenia as a
case study. METHODS: We populated a published Markov model, with recent
